News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement
|Articles|December 18, 2014

Pharm Exec eMedia Rate Card

Advertisement

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement
Pfizer’s current position reflects a misalignment. Its science is credible, its scale is unmatched, but its story is still forming. Until that story becomes clear and compelling, the valuation gap may persist. Credit: Stock.Adobe.com/Kathy images.

Pfizer at a Crossroads: Leadership, Strategy, and the Risk of a Narrative Cliff

ByThani Jambulingam, PhD
April 20th 2026
Pharmaceutical Executive Daily

Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics

ByNicholas Jacobus
April 20th 2026
President Donald J. Trump

President Trump Signs Executive Order to Accelerate FDA Reviews for Psychedelic Drugs

ByNicholas Jacobus
April 20th 2026
Stock.adobe.com acquisition

Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics

ByNicholas Jacobus
April 20th 2026
Thomas Newcomer

Addressing Regulatory Issues and the Biosimilar Void: Q&A with Thomas Newcomer

ByMike Hollan,Thomas Newcomer
April 20th 2026
Advertisement
Advertisement

Trending on PharmExec

1

Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics

2

President Trump Signs Executive Order to Accelerate FDA Reviews for Psychedelic Drugs

3

Pfizer at a Crossroads: Leadership, Strategy, and the Risk of a Narrative Cliff

4

Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics

5

Addressing Regulatory Issues and the Biosimilar Void: Q&A with Thomas Newcomer

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us